Intravenous immunoglobulin as sole therapy for systemic vasculitis

British Journal of Rheumatology

Volumn 35, Issue 11, 1996, Pages 1150-1153

  Jayne, D R W ^a   Lockwood, C M ^b  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

ANCA; IVIg; Microscopic polyangiitis; Systemic vasculitis; Wegener's granulomatosis

Indexed keywords

IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; RELAPSE; REMISSION; SYSTEMIC VASCULITIS; WEGENER GRANULOMATOSIS;

ADULT; AGED; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CREATININE; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; RADIOGRAPHY, THORACIC; URINALYSIS; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 0029964713     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Hoffman GS, Kerr GS, Leavitt R Y et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488-98.
2. Cohen Tervaert JW, Huitema MG, Hen RJ et al. Prevention of relapses in Wegener's granulomatosis by treatment based on anti-neutrophil cytoplasmic antibody titre. Lancet 1990;ii:709-11.
3. Jayne DRW, Black CM, Davies M, Fox C, Lockwood CM. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 1991;337:1137-9.
4. Lockwood CM, Thiru S, Isaacs J, Hale G, Waldmann H. Long-term remission of intractable systemic vasculitis .with monoclonal antibody therapy. Lancet 1993;341:1620-2.
5. Jayne DRW, Lockwood CM. Pooled intravenous immunoglobulin in the management of systemic vasculitis. Adv Exp Med Biol 1993;336:469-72.
6. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
7. Jayne DRW, Gaskin G, Pusey CD, Lockwood CM. ANCA and the prediction of relapse. Q J Med 1995;88:127-33.
8. Tuoso P, Mougdil A, Hay J et al. Treatment of antineutrophil cytoplasmic autoantibody-positive systemic vasculitis and glomerulonephritis with pooled intravenous immunoglobulin. Am J Kidney Dis 1992;20:504-8.
9. Richter C, Schnabel A, Csernok R, Reinhold-Keller E, Gross WL. Treatment of anti-neutrophil antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin. Clin Exp Immunol 1995;101:2-7.
10. Misbah SA, Chapel HM. Adverse effects of intravenous immunoglobulins. Drug Safety 1993;9:1-9.
11. Zhao MH, Jones SJ, Lockwood CM. Bactericidal/permeability-increasing protein (BPI) is an important antigen for anti-neutrophil cytoplasm autoantibodies (ANCA) in vasculitis. Clin Exp Immunol 1995;99:49-56.